Table 1.
Background characteristics of the patients with and without prior myocardial infarction (PMI)
| Variable | PMI patients | P value | |
|---|---|---|---|
| + | - | ||
| N | 303 | 1430 | |
| Age, y.o | 64.5 ± 10.6 | 64.5 ± 11.5 | 0.53 |
| Male, n | 272 (89.8%) | 1076 (79.82%) | <0.001 |
| BMI, kg/m2 | 24.4 ± 3.4 | 24.35 ± 3.5 | 0.81 |
| HTN, n | 225 (74.3%) | 1042 (72.9%) | 0.62 |
| DM, n | 144 (47.5%) | 536 (37.5%) | <0.01 |
| DL, n | 245 (80.9%) | 975 (68.2%) | <0.001 |
| Smoking, n | 155 (51.2%) | 626 (43.8%) | 0.02 |
| FH, n | 70 (23.1%) | 251 (17.6%) | 0.02 |
| eGFRa, ml/min/1.73 m2 | 67.1 ± 19.2 | 69.01 ± 17.3 | 0.95 |
| LDL, mg/dL | 104.1 ± 29.5 | 112.4 ± 30.5 | <0.001 |
| TGL, mg/dL | 147.3 ± 87.8 | 146.7 ± 97.2 | 0.53 |
| HbA1cb, % | 6.0 ± 1.2 | 5.8 ± 1.1 | 0.06 |
| UAc, mg/dL | 6.1 ± 1.4 | 5.8 ± 1.4 | 0.97 |
| BNPd, pg/mL | 85.1 ± 156.3 | 49.1 ± 73.3 | <0.001 |
| hs-CRP, mg/dL | 0.23 ± 0.6 | 0.26 ± 0.8 | 0.63 |
| Statin, n | 216 (71.3%) | 704 (49.2%) | <0.001 |
| BB, n | 141 (46.5%) | 528 (36.9%) | <0.01 |
| ARB or ACEi, n | 185 (61.1%) | 694 (48.5%) | <0.001 |
| EPA, μg/mL | 68.6 ± 36.4 | 74.96 ± 45.41 | 0.02 |
| DHA, μg/mL | 135.6 ± 49.1 | 145.1 ± 53.4 | <0.01 |
| AA, μg/mL | 154.4 ± 38.4 | 158.1 ± 51.6 | 0.25 |
| DHLA, μg/mL | 32.8 ± 11.8 | 33.3 ± 12.4 | 0.49 |
| EPA/AA | 0.47 ± 0.3 | 0.50 ± 0.3 | 0.08 |
| DHA/AA | 0.91 ± 0.3 | 0.96 ± 0.4 | 0.03 |
| EPA + DHA/AA + DHLA | 1.14 ± 0.5 | 1.19 ± 0.5 | 0.07 |
Continuous variables are presented as means ± standard deviations. Categorical variables are presented as percentages
BMI body mass index, HTN hypertension, DM diabetes mellitus, DL dyslipidemia, FH family history of coronary artery disease, eGFR estimated glomerular filtration rate, LDL-C low-density lipoprotein cholesterol, TGL triglycerides, HbA1c hemoglobin A1c, UA uremic acid, BNP brain natriuretic peptide, hs-CRP high-sensitivity C-reactive protein, BB beta blockers, ACE-I angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, EPA eicosapentaenoic acid, DHA docosahexaenoic acid, AA arachidonic acid, DHLA dihomo-γ-linolenic acid, EPA/AA ratio of EPA to AA levels, DHA/AA ratio of DHA to AA levels, PUFA polyunsaturated fatty acid
anumbers of patients were 247 vs. 1123 (with PMI vs. without PMI, respectively), bnumbers of patients were 245 vs. 1103 (same as above), cnumbers of patients were 110 vs. 616 (same as above), dnumbers of patients were 106 vs. 567 (same as above)